Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use

Primary tabs

field_vote: 
Average: 7 (1 vote)
Therapeutic Substance(s): 
Ther Adv Chronic Dis. Mar 2013; 4(2): 71–75.
PMCID: PMC3610260

Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use

Abstract

Irritable bowel syndrome (IBS) is the most common functional bowel disease that affects up to 15% of the US population. The majority of patients with IBS have significant bloating and gas. Recent evidence is beginning to suggest that patients with IBS may have an alteration in the gastrointestinal flora. Specifically, findings suggest that patients with IBS have excessive bacteria in the small bowel, referred to as bacterial overgrowth. Therefore there may be benefits of antibiotic-based therapies for IBS. Rifaximin is a nonabsorbable antibiotic that demonstrates no clinically relevant bacterial resistance. Some studies have demonstrated the efficacy and durable improvement of IBS symptoms after treatment with rifaximin. In this review we explore the current data showing the association of small intestinal bacterial overgrowth (SIBO) and IBS as well as review the available data on the clinical use of rifaximin in the treatment of SIBO in patients with IBS.

Keywords: irritable bowel syndrome, lactulose breath test, microbiome, rifaximin, small intestinal bacterial overgrowth